#1 Clinical Trials Search in Europe

Human Papillomavirus Type 45 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna

This article summarizes several clinical trials investigating the use of the 9-valent human papillomavirus (HPV) vaccine, specifically focusing on the active substance Human Papillomavirus Type 45 L1 Protein. These trials explore the vaccine’s efficacy, safety, and immunogenicity in different populations and for various indications, including prevention of HPV-related diseases and treatment of existing HPV-associated conditions. The studies cover diverse age groups and medical conditions, providing valuable insights into the potential applications of this vaccine beyond its current approved uses.

Table of Contents

What is the HPV Type 45 L1 Protein Vaccine?

The Human Papillomavirus (HPV) Type 45 L1 Protein vaccine is part of a 9-valent HPV vaccine called Gardasil 9. This vaccine contains proteins from nine different types of HPV, including type 45.[1] The vaccine is made using recombinant DNA technology and yeast cells to produce virus-like particles that mimic the structure of HPV but do not contain any live virus.[1]

How Does It Work?

The vaccine works by stimulating the body’s immune system to produce antibodies against the L1 protein of HPV type 45 and other included HPV types. These antibodies help protect against future infections with these HPV types. The vaccine does not treat existing HPV infections but can prevent new infections.[1]

What Does It Treat and Prevent?

The HPV Type 45 L1 Protein vaccine, as part of Gardasil 9, helps prevent:

  • Persistent anogenital HPV infection
  • Cervical, vulvar, vaginal, and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58
  • Genital warts caused by HPV types 6 and 11
  • Precancerous or dysplastic lesions caused by the 9 HPV types covered by the vaccine[1]

How is It Administered?

The vaccine is given as an intramuscular injection, typically in the upper arm or thigh. For most individuals, it is administered as a series of 2 or 3 doses:

  • For children and adolescents 9-14 years old: 2 doses, with the second dose given 6-12 months after the first
  • For individuals 15 years and older: 3 doses, with the second dose given 2 months after the first, and the third dose given 6 months after the first[1]

Effectiveness

Clinical trials have shown that the 9-valent HPV vaccine, which includes the Type 45 L1 Protein, is highly effective in preventing infections and diseases caused by the HPV types it covers. In one study, the vaccine demonstrated nearly 100% effectiveness in preventing cervical, vulvar, and vaginal precancers caused by the 7 high-risk HPV types it targets.[1]

Safety and Side Effects

The HPV Type 45 L1 Protein vaccine, as part of Gardasil 9, has been extensively tested and is considered safe. Common side effects may include:

  • Pain, swelling, or redness at the injection site
  • Headache
  • Fever
  • Nausea
  • Dizziness[1]

Serious allergic reactions are rare but possible. Patients should inform their healthcare provider of any allergies or past adverse reactions to vaccines before receiving the HPV vaccine.

Ongoing Research

Several clinical trials are currently investigating various aspects of the 9-valent HPV vaccine, including:

  • Extended dosing intervals in children and adolescents[1]
  • Effectiveness in immunocompromised individuals[2]
  • Prevention of oral HPV infections in adult males[3]
  • Use in women with high-grade cervical lesions or early cervical cancer[4]
  • Effectiveness in treating difficult-to-treat palmar or plantar warts[5]

These ongoing studies aim to expand our understanding of the vaccine’s potential uses and optimize its effectiveness in various populations.

Trial Focus Population Key Objectives Main Outcomes Measured
Extended dosing intervals Children and adolescents 9-14 years, young women 16-26 years Evaluate safety and immunogenicity of extended 2-dose regimens Antibody levels, seroconversion rates, adverse events
Immunocompromised patients Immunocompromised children and adolescents over 9 years Assess immunogenicity in various immunocompromised groups Seroconversion rates, antibody levels
Oral HPV infection prevention Adult males 20-45 years Evaluate efficacy in preventing oral HPV infection Incidence of HPV-related oral persistent infection
Vulvar HSIL recurrence prevention Women with vulvar HSIL Assess efficacy in preventing HSIL recurrence after treatment Recurrence rates, immune response, quality of life
Post-treatment for cervical lesions Women over 45 with high-grade cervical lesions Evaluate efficacy in clearing HPV after lesion treatment HPV clearance rates, recurrence of lesions
Treatment of palmar/plantar warts Patients with difficult-to-treat warts Assess efficacy in treating resistant palmar/plantar warts Wart remission rates, quality of life improvements
Pre-surgical vaccination for cervical lesions Women with high-grade cervical lesions or early cervical cancer Evaluate impact of pre-surgical vaccination on recurrence Disease recurrence rates, HPV infection persistence

FAQ

  • What is the 9-valent HPV vaccine? The 9-valent HPV vaccine is a vaccine that protects against nine types of human papillomavirus (HPV). It contains virus-like particles of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, produced using yeast cells.
  • What are the main objectives of these clinical trials? The main objectives vary across trials but generally include evaluating the vaccine's efficacy in preventing HPV infections, assessing its immunogenicity (ability to provoke an immune response), studying its effectiveness in treating existing HPV-related conditions, and confirming its safety in different populations.
  • Who are the target populations in these studies? The studies target various populations, including children and adolescents aged 9-14, adult males aged 20-45, women over 45 with high-grade cervical lesions, immunocompromised individuals, and patients with difficult-to-treat palmar or plantar warts.
  • Are there any new applications of the HPV vaccine being explored? Yes, some trials are exploring new applications such as using the vaccine to treat difficult-to-treat palmar or plantar warts, prevent recurrence of vulvar high-grade squamous intraepithelial lesions, and reduce recurrence of cervical lesions after surgical treatment.
  • How is the safety of the vaccine being assessed in these trials? Safety is assessed by monitoring adverse events, including injection-site reactions and systemic side effects. Some trials specifically look at the percentage of participants experiencing adverse events and the occurrence of serious vaccine-related adverse events.

Ongoing Clinical Trials on Human Papillomavirus Type 45 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna

Glossary

  • Human Papillomavirus (HPV): A group of viruses that can cause various types of cancer and genital warts. There are many types of HPV, some of which are targeted by the 9-valent vaccine.
  • 9-valent HPV vaccine: A vaccine that protects against nine types of HPV (6, 11, 16, 18, 31, 33, 45, 52, and 58), offering broader protection than earlier HPV vaccines.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Seroconversion: The development of detectable antibodies in the blood against a specific antigen, such as those found in a vaccine.
  • Cervical intraepithelial neoplasia (CIN): Abnormal cell growth on the surface of the cervix that can potentially lead to cervical cancer if left untreated.
  • Loop electrosurgical excision procedure (LEEP): A treatment for abnormal cells on the cervix, using a thin wire loop to remove the affected tissue.
  • Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL): Abnormal, precancerous cells found on the surface of the vulva.
  • Competitive Luminex Immunoassay (cLIA): A laboratory test used to measure antibody levels in response to vaccination.
  • Geometric Mean Titers (GMT): A way of averaging the amount of antibodies produced in response to a vaccine across a group of people.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. http://clinicaltrials.eu/trial-id/2022-500256-37-00
  2. http://clinicaltrials.eu/trial-id/2022-501413-31-00
  3. http://clinicaltrials.eu/trial-id/2022-501974-21-00
  4. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-after-treatment-for-high-grade-cervical-lesions-in-women-over-45/
  5. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-the-nonavalent-hpv-vaccine-in-treating-hard-to-treat-palmar-or-plantar-warts-in-patients-who-have-not-responded-to-two-previous-treatments/